Skip to content

Ibalizumab

CD4-directed Blocking Antibody — ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: ibalizumab-uiyk, TMB-355, TNX-355, trogarzo

EMA approvedFDA approvedOrphan designationATC J05AX23

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Ibalizumab is a drug in the CD4-directed Blocking Antibody class catalogued in DrugCentral. It was first approved by the FDA in 2018. Its mechanism of action is classified as CD4-directed Antibody Interactions and HIV 1 Post-attachment Fusion Inhibitors. DrugCentral lists 1 molecular target, including CD4. Recorded indications include Human immunodeficiency virus infection.

  • Drug class: CD4-directed Blocking Antibody; Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor.
  • Mechanism of action: CD4-directed Antibody Interactions; HIV 1 Post-attachment Fusion Inhibitors.
  • Molecular targets: CD4 (1 listed in DrugCentral).
  • Indications: Human immunodeficiency virus infection.
  • ATC code: J05AX23 (Other antivirals).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Human immunodeficiency virus infection

Mechanism & targets

Mechanism of action (MoA)CD4-directed Antibody Interactions; HIV 1 Post-attachment Fusion Inhibitors
Established pharmacologic classCD4-directed Blocking Antibody; Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor

Molecular targets (1)

TargetGeneActionActivity
T-cell surface glycoprotein CD4CD4other—

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2019-09-26EMA—Theratechnologies International Limited
2018-03-06FDA—TAIMED BIOLOGICS USAYes

ATC classification

ATC codeTherapeutic hierarchy
J05AX23ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Other antivirals

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Viral load increased206.5
Virologic failure90.3
Product dose omission issue85.2
Genotype drug resistance test positive67.3
Product use in unapproved therapeutic environment62.0
Hospitalisation55.4

Chemical structure

Molecular formula—
Molecular weight—
CAS number680188-33-4
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ibalizumab used for?

DrugCentral lists the following indications for Ibalizumab: Human immunodeficiency virus infection.

How does Ibalizumab work?

Ibalizumab is classified as CD4-directed Antibody Interactions and HIV 1 Post-attachment Fusion Inhibitors; its molecular targets in DrugCentral include CD4.

When was Ibalizumab first approved?

Ibalizumab was first approved by the FDA in 2018.

What drug class does Ibalizumab belong to?

Ibalizumab is in the CD4-directed Blocking Antibody class.

Browse: all drugs starting with I · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2018-03-06
AgencyFDA
Targets1
Indications1
Formula—
DrugCentral ID5279
Interactive profile